On May 28, 2026 Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, reported data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of patients with advanced gastrointestinal cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This data is presented in an abstract as part of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago from May 29th to June 2nd.

Abstract title: Neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for the treatment of advanced gastrointestinal cancers.
Authors: Grainne M. O’Kane, Elena Elimova, Jennifer L. Spratlin, Rachel A. Goodwin, Elaine McWhirter, Petr Kavan, Joel R. Hecht, Dae Won Kim, Do-Youn Oh, Sun Young Rha, Seung Tae Kim, Moon Ki Choi, Dong-Hoe Koo, Mark Bazett, Malcolm Snow, Michelle A. Jones, Jim Pankovich

Abstract #: e15029
View Source

Summary

Results: 109 participants with advanced gastrointestinal cancer were evaluated in the study and all but one had prior chemotherapy in the advanced setting. 95% were previously treated with oxaliplatin (65%) or cisplatin (30%). 45 patients (41%) had prior neuropathy. On study, 24 patients (22%) experienced at least one oxaliplatin-induced peripheral neuropathy (OIPN) adverse event. Lower OIPN incidence was observed across all cohorts relative to benchmarks: mCRC (14% vs. 53%), BTC (32% vs. 68%), GC (19% vs. 63%), and pancreatic cancer (29% vs. 38%). Only 9 patients (8.2%) discontinued oxaliplatin, with only 2 attributed to OIPN. Of 69 dose reductions, 16 (23%) were due to OIPN. Patients at the highest BOLD-100 dose level (625 mg/m2) had the lowest OIPN incidence.

Conclusions: Analysis of safety and dosing data from this study suggests a potential neuroprotective effect of BOLD-100 against oxaliplatin-induced peripheral neuropathy.

Bold Therapeutics is currently advancing BOLD-100 through a global Phase 2 randomized controlled trial across sites in Canada, European Union, and South Korea. This trial is investigating BOLD-100’s anticancer efficacy, but also includes important quality of life questionnaires focused on its neuroprotective potential. Please visit ClinicalTrials.gov for more information (NCT04421820).

(Press release, Bold Therapeutics, MAY 28, 2026, View Source [SID1234666163])

On May 28, 2026 RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, reported its upcoming participation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30 to June 2 in Los Angeles, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the meeting, RadioMedix leadership will participate in two sessions highlighting the Company’s work in targeted alpha therapy and lead-212 (²¹²Pb) radiopharmaceutical development.

Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder of RadioMedix, will participate in an Emerging Technology session focused on the production and clinical use of alpha emitters, where he will discuss the potential role of ²¹²Pb in radiopharmaceutical development.

Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member of RadioMedix, will present during the Oncology: Discovery & Translational Meet-the-Author Session, highlighting preclinical evaluation of ²¹²Pb-RMX-VH-PKM, a second-generation LDLR-targeting radioconjugate co-developed with Vect-Horus for pancreatic ductal adenocarcinoma (PDAC). The presentation will include data on biodistribution, dose-dependent tumor response, survival, and preliminary tolerability in preclinical PDAC models.

In addition, Dr. Delpassand will participate in the 2026 IBA KOL Meeting, hosted by IBA RadioPharma Solutions during SNMMI week, on Saturday, May 30.

RadioMedix’s participation at SNMMI 2026 coincides with the Company’s 20th anniversary, marking a meaningful moment in its evolution as the broader radiopharmaceutical field continues to gain momentum. Since its founding in 2006, RadioMedix has helped shape the growth of radiopharmaceuticals through early clinical leadership in radioligand therapy, development of infrastructure across isotope supply and manufacturing, and contributions to foundational programs that have helped define the field.

"SNMMI has long been an important forum for scientific exchange and progress in nuclear medicine, making it a meaningful setting to share our latest work and mark RadioMedix’s 20-year journey," said Dr. Delpassand. "When we founded RadioMedix, our goal was to help bring the promise of targeted radiopharmaceuticals closer to patients with difficult-to-treat cancers. Over the past two decades, that mission has guided our work across discovery, isotope supply, manufacturing, and clinical development, and it continues to shape how we approach the future of targeted radiopharmaceutical innovation."

Today, RadioMedix continues to advance precision solutions in nuclear medicine with a focus on diagnostics and targeted therapies for cancers with high unmet need. The Company’s work spans radiopharmaceutical discovery and development, isotope generation, radiochemistry, translational research, and GMP production through the SPICA Center, its 27,000 sq. ft. radiopharmaceutical manufacturing facility.

"At RadioMedix, our scientific work has always been closely tied to patient need," said Dr. Tworowska. "Our participation at SNMMI this year is an opportunity to share progress from our team, engage with the broader nuclear medicine community, and recognize the importance of continued innovation in targeted radiopharmaceuticals. This year’s SNMMI meeting is especially meaningful for us as our company celebrates 20 years of innovation in radiopharmaceutical development and clinical translation."

Presentation Details
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting

Emerging Technology Session
Session: ET03: Alpha 2: At-211 and Pb-212 (Non-CE)
Date: June 1, 2026
Session Time: 2:15 p.m. to 3:30 p.m. PT
Presentation: Pb-212: Clinical Use
Presentation Time: 2:25 p.m. to 2:35 p.m. PT
Location: 511ABC, Convention Center
Presenter: Ebrahim S. Delpassand, M.D., Chief Executive Officer and Founder, RadioMedix

Poster Presentation / Meet-the-Author Presentation
Title: Homing alpha-emitter therapy to pancreatic ductal cancer using 212Pb–labeled LDLR-targeting peptide
Session: MTA11: Oncology: Discovery & Translational Meet-the-Author Session
Date: June 2, 2026
Time: 11:30 a.m. to 12:15 p.m. PT
Location: Science Pavilion – South Hall GHJK (Convention Center)
Abstract Number: 262146
Screen: 43
Presenter: Izabela Tworowska, Ph.D., MS.Pharm, Chief Scientific Officer, Co-Founder and Board Member, RadioMedix

(Press release, RadioMedix, MAY 28, 2026, View Source [SID1234666179])

On May 28, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported the closing of its previously announced marketed public offering of units (the "Units") of the Company at a price to the public of CDN$0.50 per Unit (the "Offering"), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 8,880,000 Units. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") at an exercise price of $0.65 per Warrant Share until the date that is three years following the initial closing date of the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc., as sole agent (the "Agent"), and the Company dated May 21, 2026. An aggregate of 450,100 compensation warrants of the Company (each, a "Broker Warrant") were issued by the Company in connection with the Agency Agreement, each Broker Warrant entitling the holder to acquire one common share of the Company at an exercise price of $0.50 per share until the date that is two years following the initial closing date of the Offering.

The Offering was made pursuant to a prospectus supplement (the "Prospectus Supplement") dated May 21, 2026 to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the "Base Shelf Prospectus") filed in the Provinces of British Columbia, Alberta and Ontario. The Units may also be offered in certain other jurisdictions outside of Canada, provided that a placement therein does not give rise to any prospectus, registration or continuous disclosure obligations on the part of the Company.

The Base Shelf Prospectus, the Agency Agreement and the Prospectus Supplement are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

The securities of the Company described above have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any U.S. state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the "United States" or "U.S. Persons" (as such terms are defined in Regulation S under the 1933 Act) except pursuant to an effective registration statement under the 1933 Act and applicable U.S. state securities laws or an available exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

In addition to the above Offering and as announced previously, the Company has entered into a separate structured financing of CDN$8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP ("Sorbie").

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Medicenna Therapeutics, MAY 28, 2026, View Source [SID1234666148])

On May 28, 2026 Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) reported that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2026 Annual Meeting, which is being held from May 29-June 2, 2026, in Chicago, IL. The abstract titled "A phase 1 study to evaluate safety, tolerability, and pharmacokinetics of LNP8701 (SOS1 inhibitor) in subjects with metastatic solid tumors" has been published in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology track and can be viewed on the ASCO (Free ASCO Whitepaper) website (View Source).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports the findings from an ongoing first-in-human study of LNP8701 in patients with solid tumors. LNP8701 is an orally administered, investigational SOS1 (Son of Sevenless1) inhibitor, designed to block SOS1-mediated RAS activation, thereby limiting oncogenic signaling that promotes tumor growth. Results indicate that LNP8701 was well tolerated with desirable safety, pharmacokinetics profile and favorable anti-tumor activity. The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles (i.e., 1 year) and one patient completed 14 cycles with stable disease.

Vinita Gupta, CEO, Lupin, said, "The findings from the ongoing Phase 1 study highlight the emerging potential of LNP8701 and signal progress in our pursuit of novel therapies for difficult-to-treat cancers. We are encouraged by this momentum and remain committed to transforming scientific discovery into meaningful patient outcomes."

Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.

Details of the Abstract:

Abstract Number: e15162
Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Citation: J Clin Oncol 44, 2026 (suppl 16; abstr e15162)
DOI: 10.1200/JCO.2026.44.16_suppl.e15162
Clinical Trial Registration Number: CTRI/2024/08/072373
Abstract link: View Source

(Press release, Lupin, MAY 28, 2026, View Source [SID1234666164])

On May 28, 2026 RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, reported that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bb). Oxaliplatin is an approved and commonly used chemotherapy.

As RenovoRx continues to advance its therapeutic pipeline, it is simultaneously expanding commercialization of RenovoCath as a stand-alone device, driving adoption at leading cancer centers and building strategic and clinical collaborations that can support future revenue growth and broader platform use. RenovoCath, a patented FDA-cleared device, employs a dual-balloon infusion catheter for targeted delivery of therapeutic agents directly near a tumor.

This is RenovoRx’s second ODD in pancreatic cancer, and third designation in total, reflecting the Company’s differentiated approach to targeted intra-arterial drug-delivery using RenovoCath. RenovoRx previously received ODD for intra-arterial gemcitabine delivered via RenovoCath (known as IAG) in locally advanced pancreatic cancer (LAPC) and bile duct cancer. This designation for oxaliplatin, a platinum-based chemotherapy widely used in pancreatic cancer treatment, further supports the versatility of RenovoRx’s novel approach to delivering multiple therapeutic agents directly near the tumor site.

ODD carries meaningful regulatory and financial benefits, including:

Seven years of market exclusivity: Upon FDA approval of the designated indication (in this case, intra-arterial oxaliplatin for pancreatic cancer via RenovoCath), RenovoRx would be entitled to seven years of exclusive marketing rights, during which the FDA cannot approve the same drug for the same orphan indication by another sponsor.
Federal tax credit: A 25% tax credit on qualified clinical research expenses incurred in connection with the designated drug.
FDA application fee waiver: A waiver of the FDA application filing fee, which currently exceeds several million dollars for applications requiring clinical data.
Eligibility for orphan product development grants: Access to grant funding from the FDA’s Orphan Products Development grants program to support clinical development.
"Receiving a third ODD from the FDA is an important milestone as it provides additional validation of our strategy to build a multi-agent, targeted, drug-delivery oncology pipeline enabled by our patented RenovoCath device," said Shaun Bagai, Chief Executive Officer of RenovoRx. "Our differentiated technology is designed to deliver therapeutic agents intra-arterially across the arterial wall directly near the tumor site, with potential applications across multiple therapeutic agents and multiple cancer types. The FDA’s ODD of oxaliplatin not only expands our pipeline, but also provides valuable regulatory incentives, including seven years of potential market exclusivity and a waiver of FDA application fees that can total several million dollars. While we are laser focused on finishing our current Phase III clinical trial and advancing commercialization of RenovoCath as a standalone device, we remain committed to advancing our platform and exploring the full potential of targeted oxaliplatin delivery in patients diagnosed with difficult-to-treat cancers."

Pancreatic cancer remains one of the deadliest malignancies, with an estimated 67,530 new cases and more than 52,740 deaths expected in the United States in 2026, according to the American Cancer Society.[1] Despite advances in oncology, the disease is often diagnosed at a late stage in the majority of patients, and the five-year survival rate remains approximately 13%1, underscoring the profound unmet, yet urgent, medical need for new therapeutic approaches.

Oxaliplatin is a key component of FOLFIRINOX, one of the most widely used chemotherapy regimens for patients with advanced pancreatic cancer. RenovoRx is advancing a differentiated approach by delivering oxaliplatin directly near the tumor site using its RenovoCath device.

"This designation for intra-arterial oxaliplatin highlights the breadth of what RenovoCath may offer to pancreatic cancer patients," said Leesa Gentry, Chief Clinical Officer of RenovoRx. "Intra-arterial oxaliplatin may broaden the range of pancreatic cancer targets beyond LAPC that could benefit from localized drug-delivery with RenovoCath."

This ODD for intra-arterial oxaliplatin is separate from and in addition to RenovoRx’s existing ODD for IAG in LAPC and bile duct cancer, which also carries seven years of market exclusivity upon NDA approval by the FDA. RenovoRx’s TIGeR-PaC Phase III clinical trial evaluating IAG in LAPC continues to advance, with the Company anticipating notification of enrollment closure in June 2026 and final data readout in mid to late 2027.

(Press release, Renovorx, MAY 28, 2026, View Source [SID1234666180])